GlaxoSmithKline has taken profits in Aspen Pharmacare by selling half its stake in the South African drugmaker for $853 million , following a long investment in the firm. The sale, which was conducted through a share placing at a discount to the market price, is the latest example of GSK pruning non-core investments as it refocuses its business and works to protect its sizeable dividend payments to shareholders.